Foghorn Therapeutics Inc. (FHTX) has a negative trailing P/E of -4.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 145.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -24.99%, forward earnings yield 0.69%.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -13.5 | 0.00 | -9.06 | 0.00 | - |
| 2019 | -13.0 | -2.91 | -7.58 | 0.00 | - |
| 2020 | -10.8 | -0.30 | 5.10 | 1,734.31 | - |
| 2021 | -8.4 | -0.18 | 8.78 | 644.51 | - |
| 2022 | -2.4 | 0.42 | 2,369.23 | 13.80 | - |
| 2023 | -2.8 | 0.26 | -3.51 | 7.93 | - |
| 2024 | -3.0 | 0.09 | -5.69 | 11.46 | - |
| 2025 | -4.6 | 0.18 | -3.13 | 11.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-1.34 | $0.00 | $-26.34M | - |
| 2019 | $-1.40 | $0.00 | $-51.67M | - |
| 2020 | $-1.90 | $430K | $-69.78M | -16227.7% |
| 2021 | $-2.78 | $1.32M | $-103.23M | -7826.1% |
| 2022 | $-2.62 | $19.23M | $-108.87M | -566.2% |
| 2023 | $-2.34 | $34.16M | $-98.43M | -288.2% |
| 2024 | $-1.58 | $22.6M | $-86.62M | -383.2% |
| 2025 | $-1.18 | $30.91M | $-74.28M | -240.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.15 | $-1.33 – $-0.90 | $33M | $25.54M – $40.84M | 6 |
| 2027 | $-1.02 | $-1.22 – $-0.80 | $42.1M | $30.02M – $48.76M | 7 |
| 2028 | $-0.82 | $-1.40 – $0.13 | $58.89M | $58.03M – $59.74M | 6 |
| 2029 | $-0.82 | $-1.10 – $-0.48 | $70.08M | $47.76M – $88.35M | 4 |
| 2030 | $0.03 | $0.02 – $0.04 | $154.22M | $105.09M – $194.41M | 2 |
